Keywords:
Aerosolized delivery; antimicrobial resistance; bacteriophages; nebulization; respiratory infections
Abstract:
Pulmonary bacterial infections present a significant health risk to those with chronic respiratory diseases including cystic fibrosis and chronic-obstructive pulmonary disease. With the emergence of antimicrobial resistance, novel therapeutics are desperately needed to combat the emergence of resistant superbugs.